Lyell Immunopharma, Inc.
LYEL
Revenue
13.00k
▲10.00k▲333.33%
3 Months ChangeAssets
654.14M
▼-40.08M▼-5.77%
3 Months ChangeLiabilities
87.64M
▼-3.42M▼-3.76%
3 Months ChangeFree Cash Flow
-42.05M
▲5.70M▲11.94%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-10-31
Form 8-K
ID: 0001193125-24-248760
2024-10-24
Form 8-K
ID: 0001193125-24-242808
2024-08-07
Form 10-Q
ID: 0001628280-24-035617
2024-08-07
Form 8-K
ID: 0001628280-24-035603
2024-06-26
Form 8-K
ID: 0001193125-24-168597
2024-06-14
Form 8-K
ID: 0001193125-24-161601
2024-05-06
Form 10-Q
ID: 0001628280-24-020467
2024-05-06
Form 8-K
ID: 0001628280-24-020466
2024-02-28
Form 8-K
ID: 0001628280-24-007579
2023-11-20
Form 8-K
ID: 0001193125-23-280680